DE68913979T2 - Kationenaustauscherharze und carboxylgruppenhaltige Kunstharze enthaltende Arzneizubereitungen mit verzögerter Wirkstofffreisetzung. - Google Patents

Kationenaustauscherharze und carboxylgruppenhaltige Kunstharze enthaltende Arzneizubereitungen mit verzögerter Wirkstofffreisetzung.

Info

Publication number
DE68913979T2
DE68913979T2 DE68913979T DE68913979T DE68913979T2 DE 68913979 T2 DE68913979 T2 DE 68913979T2 DE 68913979 T DE68913979 T DE 68913979T DE 68913979 T DE68913979 T DE 68913979T DE 68913979 T2 DE68913979 T2 DE 68913979T2
Authority
DE
Germany
Prior art keywords
carboxyl
cation exchange
active substances
delayed release
resins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68913979T
Other languages
English (en)
Other versions
DE68913979D1 (de
Inventor
Rajni Jani
Robert Gregg Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27508398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68913979(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Priority claimed from JP1321616A external-priority patent/JPH0725698B2/ja
Application granted granted Critical
Publication of DE68913979D1 publication Critical patent/DE68913979D1/de
Publication of DE68913979T2 publication Critical patent/DE68913979T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
DE68913979T 1988-02-05 1989-12-01 Kationenaustauscherharze und carboxylgruppenhaltige Kunstharze enthaltende Arzneizubereitungen mit verzögerter Wirkstofffreisetzung. Expired - Lifetime DE68913979T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/154,514 US4911920A (en) 1986-07-30 1988-02-05 Sustained release, comfort formulation for glaucoma therapy
CA002004468A CA2004468C (en) 1988-02-05 1989-12-01 Sustained release, comfort formulation for glaucoma therapy
IL9252789A IL92527A (en) 1988-02-05 1989-12-01 Opthalmic pharmaceutical composition for glaucoma therapy
JP1321616A JPH0725698B2 (ja) 1984-10-31 1989-12-13 持続的放出性を有し快適に適用できる緑内障治療用の処方物
HK135695A HK135695A (en) 1986-07-30 1995-08-24 Sustained-release compositions containing cation exchange resins and polycarboxylic polymers

Publications (2)

Publication Number Publication Date
DE68913979D1 DE68913979D1 (de) 1994-04-21
DE68913979T2 true DE68913979T2 (de) 1994-09-22

Family

ID=27508398

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68913979T Expired - Lifetime DE68913979T2 (de) 1988-02-05 1989-12-01 Kationenaustauscherharze und carboxylgruppenhaltige Kunstharze enthaltende Arzneizubereitungen mit verzögerter Wirkstofffreisetzung.

Country Status (7)

Country Link
US (2) US4911920A (de)
EP (1) EP0429732B1 (de)
AU (1) AU621692B2 (de)
CA (1) CA2004468C (de)
DE (1) DE68913979T2 (de)
HK (1) HK135695A (de)
IL (1) IL92527A (de)

Families Citing this family (293)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
US5093126A (en) * 1987-09-26 1992-03-03 Alcon Laboratories, Inc. Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US5496471A (en) * 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5833665A (en) * 1990-06-14 1998-11-10 Integra Lifesciences I, Ltd. Polyurethane-biopolymer composite
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
CA2064160C (en) * 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5182102A (en) * 1991-07-12 1993-01-26 Alcon Laboratories, Inc. Anti-glaucoma compositions
CA2120603A1 (en) * 1991-10-11 1993-04-15 Louis Desantis Jr. Topical opthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use
US5320839A (en) * 1991-10-11 1994-06-14 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use
JP2873530B2 (ja) * 1991-12-13 1999-03-24 参天製薬株式会社 ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
EP0625903B1 (de) * 1992-02-21 1998-08-12 Alcon Laboratories, Inc. Topische Antiglaukoma Zusammensetzungen, enthaltend Karbonhydrasehemmer und Beta-Blocker
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
TW205503B (en) * 1992-04-24 1993-05-11 Ciba Geigy Ag Apparatus for removing components from solutions
EP0639986A1 (de) * 1992-05-13 1995-03-01 Alcon Laboratories, Inc. Topischeopthalmische zusammensetzungen, die eine kombination von calcium-antagonisten mit bekannten antiglaukommitteln enthalten
AU666957B2 (en) 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5520920A (en) * 1992-08-28 1996-05-28 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
AU674038B2 (en) * 1992-10-13 1996-12-05 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
US5340572A (en) * 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
EP0664699A1 (de) * 1993-08-13 1995-08-02 Vitaphore Corporation Arzneimittelabgabesystem auf der Basis von Hydrogelmikrokugeln
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5662919A (en) * 1994-11-21 1997-09-02 Alcon Laboratories, Inc. Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
EP1057486A1 (de) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Verwendung einer Medikamentenkombination zur Behandlung von Glaukom
ATE289815T1 (de) 1995-12-21 2005-03-15 Alcon Lab Inc Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
WO2000018316A2 (en) * 1998-09-25 2000-04-06 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy
EP1124535B1 (de) 1998-10-27 2002-12-11 Alcon Laboratories, Inc. Konservierungsmittel für lokale pharmazeutische zubereitungen enthaltend eine fettsäure/aminosäure enthaltende seife
ES2209515T3 (es) 1998-10-27 2004-06-16 Alcon Manufacturing Ltd. Sistema conservante para composiciones farmaceuticas de administracion topica.
US6444710B1 (en) 1998-10-27 2002-09-03 Alcon Manufacturing, Ltd. Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6146622A (en) * 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6258350B1 (en) 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
EP1616869B1 (de) * 1999-01-25 2012-04-04 National Jewish Health Substituierte Porphyrine und deren therapeutische Verwendung
AU4338700A (en) * 1999-05-12 2000-12-05 Alcon Laboratories, Inc. Use of polymeric adsorbents in pharmaceutical dosage forms
US6730691B1 (en) * 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
DE10115282B4 (de) * 2000-03-29 2006-03-02 Hitachi, Ltd. Einlaßluftsteuervorrichtung und Brennkraftmaschine, in der sie montiert ist
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
US20020176842A1 (en) * 2001-04-09 2002-11-28 Lyn Hughes Extended release of active ingredients
AU2002312194B8 (en) * 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
US6743439B1 (en) 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
AU2002359301B2 (en) * 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
IL165910A0 (en) * 2002-07-03 2006-01-15 Pericor Science Inc Compositions of hyaluronic acid and methods of use
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
EP1799660A2 (de) * 2004-09-17 2007-06-27 Comentis, Inc. Aminohaltige verbindungen zur inhibition der aktivität von memapsin-2-beta-sekretase und verfahren zu ihrer verwendung
US20080207527A1 (en) * 2004-09-17 2008-08-28 Comentis, Inc. Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof
US9512125B2 (en) * 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2006062731A1 (en) * 2004-11-19 2006-06-15 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
KR20080015079A (ko) * 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
WO2008005457A2 (en) 2006-06-30 2008-01-10 Sunesis Pharmaceuticals Pyridinonyl pdk1 inhibitors
US8158667B2 (en) * 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
WO2008070132A2 (en) * 2006-12-05 2008-06-12 The Royal Institution For The Advancement Of Learning/ Mcgill University Methods of use of trk receptor modulators
AU2011253937B2 (en) * 2006-12-05 2012-09-27 The Royal Institution For The Advancement Of Learning/ Mcgill University Methods of use of TRK receptor modulators
HUE043228T2 (hu) 2007-06-22 2019-08-28 Univ Texas Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
EP2178837A2 (de) * 2007-07-26 2010-04-28 Comentis, Inc. Isophthalamidderivate als hemmer der beta-sekretase-aktivität
MX2010002938A (es) * 2007-09-24 2010-04-01 Comentis Inc Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
CA2725012C (en) 2008-05-23 2019-05-07 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
WO2010011684A2 (en) * 2008-07-21 2010-01-28 The Regents Of The University Of California Prodrug and fluoregenic compositions and methods for using the same
WO2010031056A2 (en) 2008-09-15 2010-03-18 The Regents Of The University Of California Methods and compositions for modulating ire1, src, and abl activity
RU2482851C2 (ru) * 2009-02-20 2013-05-27 Микро Лабс Лимитед Хранение стабильного продукта простагландина
MX353747B (es) 2009-08-17 2018-01-26 Memorial Sloan Kettering Cancer Center Star Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos.
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
CN102665718B (zh) 2009-10-06 2016-03-09 米伦纽姆医药公司 可用作pdk1抑制剂的杂环化合物
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
PT2853262T (pt) 2009-10-26 2017-01-31 Sephoris Pharmaceuticals Llc Tratamento de queimaduras solares usando analgésicos e anti-histamínicos
CA2781056A1 (en) 2009-11-16 2011-05-19 Rebecca Maglathlin Kinase inhibitors
WO2011072257A2 (en) 2009-12-10 2011-06-16 The Regents Of The University Of California Amyloid binding agents
CA2829790C (en) 2010-03-30 2018-06-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
JP5885271B2 (ja) 2011-02-14 2016-03-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ビマトプロストのエステル誘導体の組成物および方法
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
JP6068451B2 (ja) 2011-05-17 2017-01-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
US20140221282A1 (en) 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Long duration dual hormone conjugates
AU2012279154A1 (en) 2011-07-01 2014-02-20 The Regents Of The University Of California Herpes virus vaccine and methods of use
EP2751112B1 (de) 2011-09-02 2019-10-09 The Regents of The University of California Substituierte pyrazolo[3,4-d]pyrimidine und ihre verwendung
CA2853729A1 (en) 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
EP2836482B1 (de) 2012-04-10 2019-12-25 The Regents of The University of California Zusammensetzungen und verfahren zur behandlung von krebs
EP2858500A4 (de) 2012-06-08 2016-04-06 Biogen Ma Inc Hemmer der bruton-tyrosinkinase
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CA2913736A1 (en) 2012-06-11 2013-12-19 The Regents Of The University Of California Compounds and methods of treating cancer
EP2888239B1 (de) 2012-08-27 2018-11-28 Allergan, Inc. Reduzierung der verdickung der zentralen hornhaut durch verwendung hydrophiler ester-prodrugs von beta-chlorcyclopentanen
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Compounds of pyrazolopyrimidine, as kinase inhibitors
BR112015006828A8 (pt) 2012-09-26 2019-09-17 Univ California composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
EP2909214B1 (de) 2012-10-22 2020-07-22 City of Hope Etp-derivate
US9364462B2 (en) 2012-10-30 2016-06-14 The Regents Of The University Of California Alpha-1-adrenergic receptor agonist therapy
EP2953950B1 (de) 2013-02-11 2021-01-13 The Regents of The University of California Zusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen
US9295665B2 (en) 2013-03-12 2016-03-29 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
WO2014143592A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid ip receptors
EP2968296B1 (de) 2013-03-12 2020-09-02 The Regents of the University of California Gammasekretasemodulatoren
ES2877898T3 (es) 2013-03-14 2021-11-17 Univ California Agentes mucolíticos de tiosacáridos
AU2014236370C1 (en) 2013-03-14 2019-01-17 City Of Hope 5-bromo-indirubins
EP2968270A4 (de) 2013-03-14 2016-08-17 Univ California Modulation von k2p-kanälen
WO2014146111A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Analgesic compounds and methods of use
BR112015023705A8 (pt) 2013-03-15 2020-03-17 Univ California compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
SG10201707480PA (en) 2013-03-15 2017-10-30 Verseon Corp Multisubstituted aromatic compounds as serine protease inhibitors
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
BR112015021859A2 (pt) 2013-03-15 2017-07-18 Allergan Inc bimatoprost para potencialização da produção de leptina
BR112015023214A8 (pt) 2013-03-15 2019-12-24 Verseon Corp composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2014190207A1 (en) 2013-05-22 2014-11-27 The Regents Of The University Of California Aurora kinase inhibitors
US9795691B2 (en) 2013-06-24 2017-10-24 City Of Hope Chemically-linked nanoparticles
CA2917527C (en) 2013-07-15 2022-06-14 Board Of Regents, The University Of Texas System Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
HUE053282T2 (hu) 2013-08-19 2021-06-28 Univ California Vegyületek és eljárások epilepsziás rendellenesség kezelésére
WO2015026935A2 (en) 2013-08-20 2015-02-26 City Of Hope Hdac8 inhibitors for treating cancer
WO2015031799A1 (en) 2013-08-30 2015-03-05 The Regents Of The University Of California, A California Corporation Scintillator nanocrystal-containing compositions and methods for their use
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
MY179781A (en) 2013-12-11 2020-11-13 Biogen Ma Inc Biaryl inhibitors of bruton's tyrosine kinase
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
CN106456645B (zh) 2013-12-23 2021-03-23 纪念斯隆-凯特琳癌症中心 用于放射性标记的方法和试剂
WO2015116856A2 (en) 2014-01-29 2015-08-06 City Of Hope Farnesoid x receptor antagonists
HRP20220759T1 (hr) 2014-02-11 2022-09-02 Mitokinin, Inc. Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
CA2937752C (en) 2014-02-14 2023-02-07 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
AU2015259752B2 (en) 2014-02-20 2019-06-20 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
CA2939186C (en) 2014-02-21 2023-03-07 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
AU2015235929B2 (en) 2014-03-26 2019-02-14 City Of Hope Treatment of BRCA1-defective cancer or resistant cancers
EP3129354B1 (de) 2014-04-07 2022-01-05 The Regents of the University of California Inhibitoren des enzyms der fettsäureamidhydrolase (faah) mit verbesserter oraler bioverfügbarkeit und deren verwendung als arzneimittel
BR112016026470A8 (pt) 2014-05-13 2021-07-20 Memorial Sloan Kettering Cancer Center composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
US10414814B2 (en) 2014-07-03 2019-09-17 City Of Hope Tumor-selective CTLA-4 antagonists
PL3179982T3 (pl) 2014-07-28 2023-09-25 Sun Pharma Advanced Research Company Ltd Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku
US11072681B2 (en) 2014-07-28 2021-07-27 The Regents Of The University Of California Compositions and methods of making polymerizing nucleic acids
WO2016023036A1 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California High density peptide polymers
CA2960992A1 (en) 2014-09-11 2016-03-17 The Regents Of The University Of California Mtorc1 inhibitors
KR20230145550A (ko) 2014-09-15 2023-10-17 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뉴클레오타이드 유사체
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
CN111978310A (zh) 2014-10-02 2020-11-24 阿勒根公司 γ-内酰胺的酯前药及其用途
WO2016100392A1 (en) 2014-12-15 2016-06-23 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
WO2016100914A1 (en) 2014-12-18 2016-06-23 Gourlay Steven Treatment of pemphigus
US10689423B2 (en) 2015-01-13 2020-06-23 City Of Hope CTLA4-binding protein peptide-linker masks
CN113797349A (zh) 2015-01-16 2021-12-17 希望之城 细胞穿透抗体
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
EA201992474A3 (ru) 2015-02-25 2020-05-31 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Агонисты 5ht для лечения нарушений
AU2016224975B2 (en) 2015-02-27 2020-10-22 The Regents Of The University Of California Small molecules that enable cartilage rejuvanation
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
LT3261639T (lt) 2015-02-27 2022-11-25 Verseon International Corporation Pakaitiniai pirazolo junginiai kaip serino proteazės inhibitoriai
CA2981504C (en) 2015-03-30 2023-10-24 City Of Hope Mechanically interlocking complexes
BR112017021869A2 (pt) 2015-04-10 2018-12-11 Araxes Pharma Llc compostos quinazolina substituídos e métodos de uso dos mesmos
MX2017013275A (es) 2015-04-15 2018-01-26 Araxes Pharma Llc Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
WO2016166604A1 (en) 2015-04-17 2016-10-20 Ludwig Institute For Cancer Research Ltd Plk4 inhibitors
EP3286214B1 (de) 2015-04-24 2023-12-06 The Regents of the University of California Modulatoren der ror1-ror2-bindung
CN114990141A (zh) 2015-05-15 2022-09-02 希望之城 嵌合抗原受体组合物
ES2883956T3 (es) * 2015-05-21 2021-12-09 Ophtalmis Composición oftálmica que comprende ácido lipoico y ácido hialurónico
US10787664B2 (en) 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
US10765696B2 (en) 2015-06-10 2020-09-08 City Of Hope Compositions of and methods of treatment with zwitterionic polysaccharide
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CA2991052A1 (en) 2015-07-02 2017-01-05 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017024238A1 (en) 2015-08-06 2017-02-09 City Of Hope Cell penetrating protein-antibody conjugates and methods of use
US11136301B2 (en) 2015-08-31 2021-10-05 The Regents of the University of California, A California Corporation et al. Broad spectrum antiviral compounds and uses thereof
US11124483B2 (en) 2015-09-02 2021-09-21 The Regents Of The University Of California HER3 ligands and uses thereof
JP6933644B2 (ja) 2015-09-04 2021-09-08 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ アンドロゲン受容体拮抗薬
WO2017051251A1 (en) 2015-09-25 2017-03-30 Ludwig Institute For Cancer Research Ltd 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356349A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10801026B2 (en) 2015-10-15 2020-10-13 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
BR112018008103A2 (pt) 2015-10-23 2018-11-06 Erx Pharmaceuticals, Inc. análogos de celastrol
BR112018008025A2 (pt) 2015-10-23 2018-10-23 Sunesis Pharmaceuticals, Inc. inibidores de pdk1 heterocíclicos para uso no trata-mento de câncer
US11058700B2 (en) 2015-10-28 2021-07-13 City Of Hope Macrocyclic lactones and uses thereof as modulators of purinergic receptors
MX2018005932A (es) 2015-11-12 2019-05-20 Graybug Vision Inc Microparticulas aglomerantes para terapia medica.
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US20190119259A1 (en) 2015-12-10 2019-04-25 City Of Hope Cell penetrating cyanine-coupled antibodies
DK3394046T3 (da) 2015-12-24 2022-04-04 Univ California Cftr-regulatorer og fremgangsmåder til anvendelse deraf
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
JP6931002B2 (ja) 2016-01-05 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ベンゾチアゾール両親媒性物質
US10519442B2 (en) 2016-02-11 2019-12-31 City Of Hope Twist signaling inhibitor compositions and methods of using the same
WO2017161344A1 (en) 2016-03-17 2017-09-21 The Regants Of The University Of California Compositions and methods for treating parasitic diseases
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
PT3458448T (pt) 2016-04-25 2021-09-10 Forma Therapeutics Inc Inibidores fasn para uso no tratamento de esteato-hepatite não-alcoólica
US20210323913A1 (en) 2016-04-29 2021-10-21 Board Of Regents, The University Of Texas System Sigma receptor binders
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
KR102243775B1 (ko) 2016-05-12 2021-04-22 아나코르 파마슈티칼스 인코포레이티드 옥사보롤 에스터 및 이의 용도
US10918648B2 (en) 2016-05-26 2021-02-16 The Regents Of The University Of California Estrogen receptor modulator combinations
CA3028169A1 (en) 2016-06-29 2018-01-04 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2018013609A2 (en) 2016-07-11 2018-01-18 The Regents The University Of California Synthetic melanin nanoparticles uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
US10179787B2 (en) 2016-07-29 2019-01-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
US11254667B2 (en) 2016-08-17 2022-02-22 Children's Hospital Medical Center Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
US11542261B2 (en) 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
WO2018039612A1 (en) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for promoting hair growth with mpc1 inhibitors
EP3512565A4 (de) 2016-09-13 2020-05-06 The Jackson Laboratory Gezielte dna-demethylierung und -methylierung
EP3512520B1 (de) 2016-09-15 2023-06-21 City of Hope Dithio-derivate von epidithiodiketopiperazine (etp)
US10849955B2 (en) 2016-09-28 2020-12-01 City Of Hope Methods of treating pancreatic cancer using GPCR antagonists
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
WO2018112420A1 (en) 2016-12-15 2018-06-21 The Regents Of The University Of California Compositions and methods for treating cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-on-derivate und ähnliche verbindungen als kras-g12c-modulatoren zur behandlung von krebs
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573954A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC Fusionierte bicyclische benzoheteroaromatische verbindungen und verfahren zur verwendung davon
EP3573967A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC Kondensierte bicyclische hetero-hetero-verbindungen und verfahren zur verwendung davon
BR112019019452A2 (pt) 2017-03-23 2020-04-14 Graybug Vision Inc composto, e, uso de um composto
RU2019139817A (ru) 2017-05-10 2021-06-10 Грейбуг Вижн, Инк. Микрочастицы с замедленным высвобождением и их суспензии для лекарственной терапии
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
WO2018218070A2 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
US11414419B2 (en) 2017-06-21 2022-08-16 Mitokinin, Inc. Substituted purines for the treatment of neurodegenerative and mitochondrial diseases
WO2019006371A1 (en) 2017-06-30 2019-01-03 City Of Hope COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
US11389460B2 (en) 2017-09-15 2022-07-19 City Of Hope Methods and compositions for treating endometrial cancer
EP3688028A2 (de) 2017-09-29 2020-08-05 Genentech, Inc. Antibiotische peptidkomplexe und verfahren zu deren verwendung
US20200354452A1 (en) 2017-09-29 2020-11-12 City Of Hope Cars and bispecific antibodies for treatment of mantle cell lymphoma
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
JP2020536920A (ja) 2017-10-10 2020-12-17 サイロス ファーマシューティカルズ， インコーポレイテッド ピロロトリアジン化合物およびｔａｍキナーゼを阻害する方法
WO2019079819A1 (en) 2017-10-20 2019-04-25 City Of Hope COMPOSITION AND METHOD FOR ACTIVATION OF LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV)
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
BR112020008834A2 (pt) 2017-11-02 2020-12-22 Calico Life Sciences Llc Moduladores da via de estresse integrada
AU2018358157B2 (en) 2017-11-02 2023-03-09 Abbvie Inc. Modulators of the integrated stress pathway
JP7307057B2 (ja) 2017-11-02 2023-07-11 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
CA3080959A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
EP3704098B1 (de) 2017-11-02 2024-01-24 Calico Life Sciences LLC Modulatoren eines integrierten spannungswegs
MX2020004538A (es) 2017-11-02 2020-09-18 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
CN111698989B (zh) 2017-12-07 2023-08-01 安普利克斯制药公司 杂环取代的吡啶衍生物抗真菌剂
WO2019126037A1 (en) 2017-12-19 2019-06-27 City Of Hope Modified tracrrnas grnas, and uses thereof
EP3740206B1 (de) 2018-01-16 2024-03-06 Syros Pharmaceuticals, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
WO2019143719A1 (en) 2018-01-16 2019-07-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
IL276295B2 (en) 2018-01-26 2024-02-01 Rapt Therapeutics Inc Modulators of chemokine receptors and their uses
EP3765459A1 (de) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituierte imidazopyridine als inhibitoren von plasmakallikrein und verwendungen davon
EP3784233A4 (de) 2018-04-27 2022-03-02 Spruce Biosciences, Inc. Verfahren zur behandlung von hoden-und eierstock-nebennierentumoren
CA3098698A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
US20190336609A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
US11931345B2 (en) 2018-05-04 2024-03-19 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases
WO2019236631A1 (en) 2018-06-05 2019-12-12 Rapt Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
KR102533477B1 (ko) 2018-06-21 2023-05-18 칼리코 라이프 사이언시스 엘엘씨 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법
JP2021530445A (ja) 2018-06-25 2021-11-11 アンプリックス ファーマシューティカルズ，インク． 複素環およびアミノ基によって置換されたピリジン誘導体
CN112867503A (zh) 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
TWI771621B (zh) 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
EP3856742A4 (de) 2018-11-01 2022-06-22 Lynk Pharmaceuticals Co. Ltd. Tricyclische janus-kinase-1-inhibitoren und zusammensetzungen und verfahren dafür
JP7204005B2 (ja) 2019-03-14 2023-01-13 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
AU2020264485A1 (en) 2019-04-30 2021-12-02 Abbvie Inc. Substituted cycloalkyls as modulators of the integrated stress pathway
US10973780B2 (en) 2019-05-15 2021-04-13 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection
BR112022004475A2 (pt) 2019-09-18 2022-05-31 Novartis Ag Proteínas de fusão nkg2d e usos das mesmas
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
JP2022548696A (ja) 2019-09-18 2022-11-21 武田薬品工業株式会社 血漿カリクレインインヒビター及びその使用
WO2021097339A1 (en) 2019-11-13 2021-05-20 Rapt Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
AU2020407648A1 (en) 2019-12-18 2022-06-30 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
EP4153564A1 (de) 2020-05-19 2023-03-29 Cybin IRL Limited Deuterierte tryptaminderivate und verfahren zur verwendung
KR20230053611A (ko) 2020-08-18 2023-04-21 사이빈 아이알엘 리미티드 펜에틸아민 유도체, 조성물, 및 사용 방법
PE20231656A1 (es) 2020-11-02 2023-10-17 Trethera Corp Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos
CA3198795A1 (en) 2020-11-18 2022-05-27 Jeffrey Becker Complexing agent salt formulations of pharmaceutical compounds
WO2022133237A2 (en) 2020-12-18 2022-06-23 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
EP4308229A1 (de) 2021-03-17 2024-01-24 Takeda Pharmaceutical Company Limited Plasmakallikreinhemmer
JP2024510502A (ja) 2021-03-17 2024-03-07 武田薬品工業株式会社 血漿カリクレインのイミダゾピリジニル阻害剤
WO2022197789A1 (en) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Polycyclic inhibitors of plasma kallikrein
KR20240004296A (ko) 2021-03-17 2024-01-11 다께다 파머수티컬 컴패니 리미티드 혈장 칼리크레인의 헤테로아릴 억제제
WO2022197756A1 (en) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Plasma kallikrein inhibitors
WO2023156450A1 (en) 2022-02-15 2023-08-24 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use
WO2023156453A1 (en) 2022-02-15 2023-08-24 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
US20230322741A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3867519A (en) * 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
US3987163A (en) * 1973-07-27 1976-10-19 Burton, Parsons And Company, Inc. Polystyrene sulfonate containing opthalmic solutions
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4127674A (en) * 1977-03-21 1978-11-28 Allergan Pharmaceuticals, Inc. Method of treatment for glaucoma
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4521414A (en) * 1981-06-18 1985-06-04 The Texas A&M University System Ophthalmic compositions and their use for treating elevated intraocular pressure and glaucoma
JPS5858146A (ja) * 1981-10-05 1983-04-06 Tanabe Seiyaku Co Ltd 速放性マイクロカプセル
NZ219925A (en) * 1986-07-30 1989-06-28 Pennwalt Corp Polymer-treated sulphonic acid cationic exchange resin particles

Also Published As

Publication number Publication date
CA2004468C (en) 1996-10-01
CA2004468A1 (en) 1991-06-01
DE68913979D1 (de) 1994-04-21
HK135695A (en) 1995-09-01
AU4575389A (en) 1991-08-01
EP0429732A1 (de) 1991-06-05
US4911920A (en) 1990-03-27
AU621692B2 (en) 1992-03-19
US5635172A (en) 1997-06-03
EP0429732B1 (de) 1994-03-16
IL92527A (en) 1994-02-27

Similar Documents

Publication Publication Date Title
DE68913979D1 (de) Kationenaustauscherharze und carboxylgruppenhaltige Kunstharze enthaltende Arzneizubereitungen mit verzögerter Wirkstofffreisetzung.
DE3880593D1 (de) Arzneizubereitungen mit retardierter wirkstofffreisetzung.
DE3650657D1 (de) Pharmazeutische Formulierung mit gesteuerter Freigabe
PT78732B (de) 13-alpha-alkylgonane deren herstellung und diese enthaltende pharmazeutische praeparate
DE69000881T2 (de) 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe.
PT81969A (de) 11beta-phenyl-gonane deren herstellung und diese enthaltende pharmazeutische praparate
EP0224146A3 (en) Pharmaceutical preparation for the controlled release of active ingredients
NO882075D0 (no) 9-alfa-hydroksysteroider, deres fremstilling, en fremgangsmaate for fremstilling av de tilsvarende 9(11)-dehydro-derivater samt farmasoeytiske preparater inneholdend
DE3688710T2 (de) Isolierung und pharmazeutische Verwendung von Hyaluronidase und diese enthaltende pharmazeutische und tierärztliche Präparate.
IT1235532B (it) Composti carbossiammidici, procedimenti per la preparazione dei medesimi e composizione farmaceutica contenente i medesimi
EP0193415A3 (en) Spiro-3-heteroazolidine compounds and salts thereof, their preparation and pharmaceutical agents thereof
NO862096L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator.
DE3882157D1 (de) Nichtsteroide antientzuendungswirkstoffe enthaltende pharmazeutische zubereitungen.
DE68917499D1 (de) Catechol-Derivate und sie enthaltende pharmazeutische Präparate.
DE3678643D1 (de) Partikel mit konstanter wirkstofffreisetzung.
DE3678641D1 (de) Partikel mit konstanter wirkstofffreisetzung.
DE68902300T2 (de) Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure.
DK496889A (da) Peptidholdigt farmaceutisk praeparat
ZA906264B (en) Microencapsulated taste-masked water-insoluble nsaid drug materials
DK256290D0 (da) Farmaceutisk praeparat indeholdende deoxyribonucleosider til saarheling
IL81990A0 (en) Compounds and pharmaceutical preparations having calcium regulatory activity
GB2181053B (en) Pharmaceutical formulations with controlled release of the active substance
NO305750B1 (no) Substituerte benzensulfonylureaer og deres anvendelse for fremstilling av farmas°ytiske preparater samt farmas°ytiske preparater inneholdende forbindelsene
DE68909555D1 (de) Pyridylketoximether-verbindung und diese enthaltende pharmazeutische zusammensetzung.
SG103391G (en) Pharmaceutical formulations with controlled release of the active substance

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings